![Fig. 1. Inhibition of gp120 binding on MDDC. / (A) Inhibition of gp120 binding to MDDCs by mannan; 1 × 106 cells/mL were incubated with mannan ranging from 50 μg to 5 mg/mL for 30 minutes at 4°C. The b-gp120 was added at 3-fold excess (9 μg/mL) and incubated for 30 minutes at 4°C. The b-gp120 was detected via streptavidin Oregon Green 488 and fluorescence measured by flow cytometry as described. (B,C) Inhibition of gp120 binding to MDDCs by CD4 mAbs (Leu3a, Q4120, OKT4). In panel B, cells were preincubated with mAbs to CD4 (ranging from 0.05 μg/mL to 25 μg/mL) for 30 minutes at 4°C. In panel C, cells were also incubated with 5 mg/mL mannan in addition to the CD4 mAb Leu3a. The b-gp120 was incubated and detected as in panel A. Percent DC-gp120 binding was calculated as follows: [(sample fluorescence intensity − mean negative control fluorescence intensity)/mean positive control fluorescence intensity] × 100. Positive control cells were treated with b-gp120 in the absence of inhibitors. Negative controls consisted of cells with identical inhibitors but no b-gp120.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/98/8/10.1182_blood.v98.8.2482/6/h82011629001.jpeg?Expires=1735839252&Signature=Jqpmbcz3UoxDbBZSp4W2W8MLrJ4OjFIpl7L57YEyvz-yToWQNsrbSBW~139beZwa4IwKjI0J0bG~EPxFYqnlBOzmk340FxbQg69JTzPF~gOuJi8O~5PX8rSJeS0wxfS2LcRoSJmKPbzg-0jB1rpYlVE0VCZFRzK-i9XbU7xmgSjOdRYG5ZwdLIRxYrkkSMM4fQ6kUwhv3BLLHmqJL2CNNdvV7Se2QM2UgPRZl3OTlUg6QstYUeMVzRZG1EIG~8FFcHsrABdxCdzMCFBrkDpnG77beFMlkEBqxoIBiGplALYjHZNKmOUXygHhX3-521cZhCWgi~r6XgIf~7pKwtKdGw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Inhibition of gp120 binding on MDDC.
(A) Inhibition of gp120 binding to MDDCs by mannan; 1 × 106 cells/mL were incubated with mannan ranging from 50 μg to 5 mg/mL for 30 minutes at 4°C. The b-gp120 was added at 3-fold excess (9 μg/mL) and incubated for 30 minutes at 4°C. The b-gp120 was detected via streptavidin Oregon Green 488 and fluorescence measured by flow cytometry as described. (B,C) Inhibition of gp120 binding to MDDCs by CD4 mAbs (Leu3a, Q4120, OKT4). In panel B, cells were preincubated with mAbs to CD4 (ranging from 0.05 μg/mL to 25 μg/mL) for 30 minutes at 4°C. In panel C, cells were also incubated with 5 mg/mL mannan in addition to the CD4 mAb Leu3a. The b-gp120 was incubated and detected as in panel A. Percent DC-gp120 binding was calculated as follows: [(sample fluorescence intensity − mean negative control fluorescence intensity)/mean positive control fluorescence intensity] × 100. Positive control cells were treated with b-gp120 in the absence of inhibitors. Negative controls consisted of cells with identical inhibitors but no b-gp120.
